Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENTHRANE vs RISPERDAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Penthrane (methoxyflurane) is a volatile halogenated ether anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and central nervous system depression. It also sensitizes the myocardium to catecholamines and produces nephrotoxic fluoride ions via metabolism.
Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.
Induction and maintenance of general anesthesia,Analgesia for short-duration procedures (off-label)
Schizophrenia (FDA-approved),Bipolar I disorder (acute manic or mixed episodes) (FDA-approved),Irritability associated with autistic disorder (FDA-approved),Treatment-resistant depression (adjunctive to antidepressants) (off-label),Tourette's disorder (off-label),Obsessive-compulsive disorder (adjunctive) (off-label),Post-traumatic stress disorder (off-label),Delirium (off-label)
0.2-0.5% inspired concentration via inhalation for analgesia; for general anesthesia, up to 2% inspired via vaporizer.
2-8 mg orally once daily or divided twice daily; maximum 16 mg/day
Terminal elimination half-life ranges from 1.5 to 4 hours, reflecting slow washout due to high fat solubility and prolonged release from adipose tissue. Clinically, this can lead to prolonged sedation and risk of fluoride-induced nephrotoxicity.
20 hours (parent drug), 23 hours (active metabolite 9-hydroxyrisperidone). Steady state reached in 5-6 days. Extended in elderly and hepatic/renal impairment.
Primarily hepatic via cytochrome P450 enzymes (CYP2E1), releasing inorganic fluoride ions; approximately 50% is metabolized.
Risperidone is extensively metabolized by cytochrome P450 2D6 (CYP2D6) to its active metabolite, 9-hydroxyrisperidone (paliperidone). A minor pathway involves CYP3A4 and CYP3A5. The metabolite is further metabolized via N-dealkylation and oxidative pathways.
Approximately 50% of absorbed methoxyflurane is eliminated unchanged by the lungs; the remainder is metabolized, primarily via hepatic CYP450 isoenzymes, with fluoride ion and other metabolites excreted renally. Biliary/fecal elimination is negligible (<1%).
Renal: 70% (30% as unchanged drug, 40% as metabolites), Fecal/Biliary: 14%
40–50% bound to plasma proteins, primarily albumin.
90% (albumin and alpha-1-acid glycoprotein). Active metabolite 77% bound.
Vd approx 2.0–3.5 L/kg, reflecting extensive distribution into adipose tissue and slow equilibration.
1-2 L/kg. Large Vd indicates extensive tissue distribution and penetration into CNS.
Inhalation: 100% via pulmonary route (no first-pass metabolism). Not administered orally or parenterally in clinical use.
Oral: 70% (with extensive first-pass metabolism). IM: 100% for immediate-release. Long-acting IM: fraction absorbed over depot injection.
No specific GFR-based dose adjustments; use with caution in severe renal impairment due to potential nephrotoxicity from fluoride ions.
Cr Cl <30 m L/min: initial 0.5 mg twice daily, increase by 0.5 mg increments; max 3 mg/day
No specific Child-Pugh based modifications; use with caution in severe hepatic impairment due to potential hepatotoxicity.
Child-Pugh class A or B: initial 0.5 mg twice daily, increase by 0.5 mg increments; max 3 mg/day; Child-Pugh C: not studied
Not recommended for children due to risk of nephrotoxicity and hepatotoxicity; alternative agents preferred.
13-17 yr: 0.5 mg once daily, titrate by 0.5-1 mg/day at ≥24 hr intervals; target 3 mg/day; max 6 mg/day. 10-12 yr: 0.5 mg once daily, titrate by 0.5 mg/day; target 1-2.5 mg/day; max 3 mg/day
Use lower inspired concentrations (e.g., 0.2-0.5%) and monitor closely for hypotension and respiratory depression; consider reduced dose due to decreased renal and hepatic function.
Initial 0.5 mg twice daily; increase by 0.5 mg increments; max 3 mg/day; monitor for orthostatic hypotension and sedation
Not approved for use in the United States; has been associated with fatal hepatotoxicity and nephrotoxicity, particularly when used at high doses or for prolonged periods.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis.
Hepatotoxicity and nephrotoxicity due to fluoride ion accumulation; myocardial sensitization to catecholamines; malignant hyperthermia risk; respiratory depression; dose-dependent renal impairment.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in elderly with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Hyperglycemia and diabetes mellitus,Weight gain,Dyslipidemia,Orthostatic hypotension and syncope,Seizures,Leukopenia, neutropenia, and agranulocytosis,QT interval prolongation,Hyperprolactinemia,Body temperature dysregulation,Dysphagia,Priapism,Thrombotic thrombocytopenic purpura (TTP)
Hypersensitivity to halogenated anesthetics; known or suspected susceptibility to malignant hyperthermia; significant hepatic or renal impairment; concurrent use of nephrotoxic agents.
Hypersensitivity to risperidone, paliperidone, or any component of the formulation
No direct food interactions are documented. However, methoxyflurane metabolism may be affected by hepatic enzyme inducers or inhibitors. Avoid excessive consumption of grapefruit juice as it may inhibit CYP2E1, potentially altering drug metabolism. Maintain adequate hydration to help reduce the risk of nephrotoxicity.
Grapefruit juice may increase risperidone levels; avoid concurrent use. Risperidone can be taken with or without food. High-fat meals do not affect absorption. Weight gain is common; encourage heart-healthy diet. Alcohol may exacerbate CNS depression and orthostatic hypotension; advise avoidance.
First trimester: Limited human data; animal studies show fetal toxicity at high doses. Potential risk of congenital anomalies cannot be excluded. Second and third trimesters: May cause fetal hypotension and bradycardia; avoid prolonged or high-dose exposure. Near term: Risk of neonatal respiratory depression.
First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Risk of extrapyramidal symptoms and/or withdrawal symptoms in neonates if exposed during third trimester. Overall, not considered a major teratogen.
Unknown if excreted in human milk. M/P ratio not established. Caution advised; consider benefits of breastfeeding vs. potential risk to infant.
Risperidone and its active metabolite 9-hydroxyrisperidone are excreted in breast milk. Milk-to-plasma ratio (M/P) approximately 0.42-0.44. Relative infant dose is about 4-9% of maternal weight-adjusted dose. Monitor infant for sedation, poor feeding, and extrapyramidal symptoms. Consider benefits of breastfeeding vs. risk.
No specific dose adjustments recommended due to limited data. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy; use lowest effective dose for shortest duration.
Increased plasma volume and hepatic metabolism may lower risperidone concentrations, especially in second and third trimesters. Dose adjustments may be needed; monitor clinical response and consider therapeutic drug monitoring. No standard dose adjustment recommendation; titrate to effect.
Penthrane (methoxyflurane) is a volatile inhalational anesthetic with potent analgesic properties at subanesthetic doses. It is primarily used for emergency pain relief via a handheld inhaler (Penthrox). Key clinical pearls: (1) Nephrotoxicity is dose-dependent due to inorganic fluoride metabolites; limit exposure to a maximum of 6 m L over a week. (2) Avoid concurrent use of tetracyclines or aminoglycosides due to increased nephrotoxic risk. (3) Caution in patients with renal impairment, hepatic disease, or malignant hyperthermia susceptibility. (4) Rapid onset of analgesia within 2-5 breaths; monitor for excessive sedation or respiratory depression. (5) Do not use in patients with cardiovascular instability or hypovolemia as it can cause myocardial depression.
Risperdal (risperidone) is a second-generation antipsychotic with high affinity for D2 and 5-HT2A receptors. Monitor for orthostatic hypotension during dose titration, especially in elderly. QT prolongation risk is dose-dependent; avoid with hypokalemia, hypomagnesemia, or concomitant QT-prolonging drugs. Therapeutic response for psychosis may take 2-4 weeks. For agitation, consider sublingual or IM formulations. Extrapyramidal symptoms are dose-related; more common at doses >6 mg/day. Prolactin elevation is more pronounced than with other atypical antipsychotics; monitor for galactorrhea, gynecomastia, menstrual irregularities. Weight gain and metabolic syndrome require baseline and periodic monitoring of BMI, fasting glucose, and lipids. Risk of tardive dyskinesia with long-term use. In elderly with dementia-related psychosis, increased mortality.
Penthrane is used to relieve moderate to severe pain from trauma or procedures.,Inhale from the device as instructed; do not swallow the liquid.,You may feel drowsy or dizzy; avoid driving or operating machinery for at least 24 hours after use.,Do not consume alcohol or take other central nervous system depressants without consulting your doctor.,Report any signs of kidney injury such as decreased urination, swelling, or fatigue.,Use only as directed and do not exceed the prescribed dose or duration.,Keep the inhaler out of reach of children and do not share with others.
Take risperidone exactly as prescribed; do not crush or chew tablets.,Avoid alcohol and grapefruit juice as they may worsen side effects.,Rise slowly from sitting or lying to prevent dizziness or fainting.,Report unusual muscle stiffness, tremors, or restlessness immediately.,Notify your doctor if you experience breast swelling, discharge, or sexual dysfunction.,Risperidone may cause drowsiness; avoid driving until you know how the drug affects you.,Do not stop abruptly; withdrawal may cause nausea, vomiting, or insomnia.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.,Avoid overheating or dehydration; increased body temperature may occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENTHRANE vs RISPERDAL, answered by our medical review team.
PENTHRANE is a Inhaled Anesthetic that works by Penthrane (methoxyflurane) is a volatile halogenated ether anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and central nervous system depression. It also sensitizes the myocardium to catecholamines and produces nephrotoxic fluoride ions via metabolism.. RISPERDAL is a Atypical Antipsychotic that works by Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENTHRANE and RISPERDAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENTHRANE is: 0.2-0.5% inspired concentration via inhalation for analgesia; for general anesthesia, up to 2% inspired via vaporizer.. The standard adult dose of RISPERDAL is: 2-8 mg orally once daily or divided twice daily; maximum 16 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENTHRANE and RISPERDAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENTHRANE is classified as Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Potential risk of congenital anomalies cannot be excluded. Second and third trimesters: May c. RISPERDAL is classified as Category C. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Risk of extrapyramidal symptoms an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.